A Phase 1, Randomized, Double-blind, Placebo-Controlled, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of Intravenous ORT247 in Healthy Volunteers
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs ORT 247 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; First in man
- Sponsors Orthogonal Neuroscience
- 17 Jan 2025 New trial record